大环内酯类抗生素市场规模、份额和成长分析（按药物、管理、适应症、最终用户和地区）- 产业预测 2025-2032

2023 年全球大环内酯类抗生素市场规模价值 58 亿美元，预计将从 2024 年的 59.3 亿美元增长到 2032 年的 71.2 亿美元，预测期内（2025-2032 年）的复合年增长率为 2.3%。

随着全球感染疾病发生率的上升，大环内酯类抗生素市场预计将出现成长。大环内酯类抗生素的特征是具有大环内酯结构，能与细菌核醣体结合并抑制蛋白质合成，对多种感染疾病有效，包括性行为感染和肺炎、支气管炎等呼吸道疾病。根据美国生物技术资讯中心的数据，肺炎的发生率相当高，全球每 1,000 人中有 1.5 至 14 例，美国每 10,000 人中有 24.8 例，尤其是老年人。仿製药的普及进一步推动了对这些抗生素的需求不断增长，各公司都在努力开发与原始大环内酯类学名药，以增加其在市场上的份额。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

大环内酯类抗生素市场规模（按药物类型和复合年增长率） (2025-2032)

• 市场概况
• 阿奇霉素
• 克拉霉素
• 红霉素
• 非达霉素
• 泰利霉素

大环内酯类抗生素市场规模（依给药模式及复合年增长率）（2025-2032）

• 市场概况
• 口服
• 肠外

大环内酯类抗生素市场规模（依适应症和复合年增长率） (2025-2032)

• 市场概况
• 肺炎霉浆菌感染疾病
• 退伍军人菌或百日咳桿菌
• 猫抓病的症状
• 桿菌性肝血管瘤
• 爱滋病患者肝紫斑
• 脑红紫杉体病
• 无併发症的皮肤感染疾病
• 其他的

大环内酯类抗生素市场规模（依最终用户和复合年增长率） (2025-2032)

• 市场概况
• 医院
• 皮肤科诊所
• 製药公司
• 其他的

大环内酯类抗生素市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Pfizer Inc.（USA）
• Merck & Co., Inc.（USA）
• AbbVie Inc.（USA）
• Sanofi SA（France）
• Novartis AG（Switzerland）
• GlaxoSmithKline plc（UK）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Mylan NV（USA）
• Daiichi Sankyo Company, Limited（Japan）
• Sun Pharmaceutical Industries Limited（India）
• Cipla Limited（India）
• Lupin Limited（India）
• Zydus Lifesciences Limited（India）
• Alkem Laboratories Ltd.（India）
• Zhejiang Guobang Pharmaceutical Co., Ltd.（China）
• Bristol Myers Squibb（USA）
• Abbott Laboratories（USA）
• Eli Lilly and Company（USA）
• Amgen Inc.（USA）
• Sandoz International GmbH（Germany）

结论和建议

Global Macrolide Antibiotics Market size was valued at USD 5.8 billion in 2023 and is poised to grow from USD 5.93 billion in 2024 to USD 7.12 billion by 2032, growing at a CAGR of 2.3% during the forecast period (2025-2032).

The macrolide antibiotic market is poised for growth, driven by a rising global prevalence of infectious diseases. Macrolides, characterized by their macrocyclic lactone structure and ability to inhibit protein synthesis by binding to the bacterial ribosome, are effective against various infections, including sexually transmitted diseases and respiratory ailments like pneumonia and bronchitis. The National Centre for Biotechnology Information reports significant rates of pneumonia, with incidences ranging from 1.5 to 14 cases per 1,000 people globally, and 24.8 cases per 10,000 in the United States, especially among older adults. The increasing demand for these antibiotics is further bolstered by the availability of generic options, as companies strive to develop equivalents to branded macrolides, enhancing their market presence.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Macrolide Antibiotics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Macrolide Antibiotics Market Segmental Analysis

Global Macrolide Antibiotics Market is segmented by Drugs, Administration, Indication, End User and region. Based on Drugs, the market is segmented into Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin and Telithromycin. Based on Administration, the market is segmented into Oral and Parenteral. Based on Indication, the market is segmented into Infection due to mycoplasma pneumonia, Legionella sp,or Bordetella pertussis, Symptomatic cat-scratch disease, Bacillary angiomatosis, Peliosis hepatis in patients with AIDS, Cebebral taxoplasmosis, Uncomplicated skin infection and Others. Based on End User, the market is segmented into Hospitals, Dermatology clinics, Pharmaceutical companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Macrolide Antibiotics Market

The global macrolide antibiotics market is experiencing significant growth driven by emerging trends in developing nations such as China, India, and Brazil. These markets present substantial opportunities due to their large populations and increasing healthcare expenditures, which contribute to a rising demand for antibiotics. As bacterial infections become more prevalent in these regions, the need for effective treatment solutions continues to escalate. Consequently, manufacturers of macrolide antibiotics can expand their market presence and capitalize on the growing demand for innovative and efficient alternatives. This combination of factors positions the macrolide antibiotics market for remarkable expansion in the coming years.

Restraints in the Global Macrolide Antibiotics Market

The Global Macrolide Antibiotics market faces significant constraints due to the increasing prevalence of antibiotic-resistant microorganisms, particularly to macrolides. This resistance primarily arises from the overuse and misuse of antibiotics, posing a critical challenge to the long-term viability of macrolide treatments for bacterial infections. As the effectiveness of these drugs diminishes, the market potential for macrolide antibiotics is compromised. Addressing the escalating issue of antibiotic resistance necessitates the development of new pharmacological options and alternative therapeutic strategies to ensure effective treatment and mitigate the impact of resistant bacteria on public health.

Market Trends of the Global Macrolide Antibiotics Market

The Global Macrolide Antibiotics market is increasingly shaped by the urgent need to address bacterial resistance and enhance treatment efficacy. Pharmaceutical companies are innovating to develop new macrolide derivatives and advanced formulations, focusing on improving pharmacokinetics and expanding their spectrum of activity. This trend reflects a commitment to counteract evolving microbial threats while optimizing existing macrolide treatments for a wide range of bacterial infections. Additionally, increasing awareness of antibiotic resistance is driving research investments, suggesting a dynamic market landscape poised for growth. Consequently, the macrolide antibiotic sector is adapting to meet the pressing challenges posed by resistant pathogens in the healthcare environment.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Macrolide Antibiotics Market Size by Drugs & CAGR (2025-2032)

• Market Overview
• Azithromycin
• Clarithromycin
• Erythromycin
• Fidaxomicin
• Telithromycin

Global Macrolide Antibiotics Market Size by Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral

Global Macrolide Antibiotics Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Infection due to mycoplasma pneumonia
• Legionella sp,or Bordetella pertussis
• Symptomatic cat-scratch disease
• Bacillary angiomatosis
• Peliosis hepatis in patients with AIDS
• Cebebral taxoplasmosis
• Uncomplicated skin infection
• Others

Global Macrolide Antibiotics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Dermatology clinics
• Pharmaceutical companies
• Others

Global Macrolide Antibiotics Market Size & CAGR (2025-2032)

• North America (Drugs, Administration, Indication, End User)
  • US
  • Canada
• Europe (Drugs, Administration, Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drugs, Administration, Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drugs, Administration, Indication, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drugs, Administration, Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkem Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zhejiang Guobang Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations